Europe
All Resolutions Proposed by the Company’s Management Approved
Biopharma companies from across the globe strengthen their leadership teams with key executive appointments.
Research Roundup for Friday, May 24.
Investors and analysts get a close-up look at the Swiss pharma giant’s pipeline and growth strategies.
In addition to education and training, it will offer Bayer’s complete portfolio of recombinant Factor VIII treatments to healthcare providers in more than 60 countries.
The company focuses on developing a novel class of drugs called Bicycles. Bicycles are fully synthetic short peptides constrained to form two loops—hence “bi” cycles—that stabilize their structural geometry.
Pharming Group N.V. announces that at its Annual General Meeting of shareholders, all proposals were approved.
Martinsried/Munich Medigene AG, a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, reports on the Company’s Annual General Meeting which was held in Munich.
Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Company’s AGM held earlier the Company provided the following review of key aspects of its business and growth strategy.
Motif Bio plc announced that the Company has signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evaluating iclaprim in an in vitro model of ocular toxoplasmosis.
PRESS RELEASES